文献速递真菌感染

米卡芬净预防期间血清半乳甘露聚糖检测的误导效应

The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin.
PubMed 文献 · Clin Microbiol Infect · 2017-05-12

该回顾性研究纳入146例接受米卡芬净预防的高危血液病患者,评估常规血清半乳甘露聚糖(sGM)试验诊断侵袭性曲霉病(IA)的性能。结果显示突破性IA发生率为2.7%,76%为真阴性,21.2%为假阳性,无假阴性;监测性sGM阳性预测值仅3.2%,但诊断性sGM在症状患者中仍有用。

要点

  • 米卡芬净预防期间监测性sGM假阳性率高,阳性预测值仅3.2%。
  • 监测性sGM阴性预测值100%,但结果多为阴性或假阳性,监测不必要。
  • 对出现症状的患者,sGM仍可用于诊断突破性IA。

核心结论

  • 接受米卡芬净预防的无症状患者无需常规监测sGM,因结果要么阴性要么假阳性。
  • sGM对预防期间出现症状患者的突破性IA诊断仍有用。

研究设计与样本

  • 回顾性研究纳入146例可评估的高危IA发作期血液病患者,均接受米卡芬净预防且至少有一次sGM结果。

主要发现

  • 146例中4例为真阳性(可能突破性IA),突破性IA发生率为2.7%。
  • 111/146(76%)为真阴性,31/146(21.2%)为假阳性,未检测到假阴性。
  • 31例假阳性中除1例外均来自监测性GM检测,其中8例(25.8%)接受了高分辨率CT扫描且均为阴性。
  • 监测性sGM的阳性预测值为3.2%(1/31),阴性预测值为100%(110/110)。
  • 诊断性sGM的阳性预测值为75%(3/4),阴性预测值为100%(1/1)。

关键数值与推荐

  • 监测性sGM阳性预测值3.2%(1/31),阴性预测值100%(110/110)。
  • 诊断性sGM阳性预测值75%(3/4),阴性预测值100%(1/1)。

临床怎么用

  • 对接受米卡芬净预防的无症状高危血液病患者,不应常规监测sGM。
  • 对预防期间出现症状的患者,仍可使用sGM辅助诊断突破性IA。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the performance of the routine serum galactomannan (sGM) assay in the diagnosis of invasive aspergillosis (IA) in high-risk haematology patients receiving prophylaxis with micafungin. METHODS: Retrospective study including all haematological patients who received prophylaxis with micafungin during high-risk IA episodes (neutropenic patients after chemotherapy for acute myeloid leukaemia/myelodysplastic syndrome; allogeneic haematopoietic stem-cell transplantation during early neutropenic phase or graft-versus-host disease requiring high prednisone doses) and for whom at least one sGM result was available. Episodes were classified as follows: true-positive (positive GM in the context of IA), false-positive (positive GM result in patients who had no evidence of IA), true-negative (negative GM test results and no IA), or false-negative (negative GM test in the context of IA). Non-evaluable patients were excluded. RESULTS: Among 146 evaluable episodes, four were true-positive in the context of probable breakthrough IA (incidence of breakthrough IA, 2.7%); 111/146 high-risk episodes (76%) were considered true-negative and 31/146 (21.2%) were considered false-positive. No false-negative episodes were detected. All but one of the false-positive episodes were detected in surveillance GM tests, leading to high-resolution CT scans in eight cases (8/31; 25.8%), all of which were negative. The positive predictive and negative predictive values of sGM for surveillance and diagnostic approaches were 3.2% (1/31) and 100% (110/110) and 75% (3/4) and 100% (1/1), respectively. CONCLUSIONS: Surveillance of asymptomatic patients receiving prophylaxis with micafungin using sGM is unnecessary, because the results are either negative or false-positive. However, sGM remains useful in the diagnosis of breakthrough IA in symptomatic patients during prophylaxis.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Vena A, Bouza E, Álvarez-Uría A, et al. The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin. Clin Microbiol Infect. 2017. PMID: 28506782. doi:10.1016/j.cmi.2017.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。